Surrozen (NASDAQ:SRZN – Get Free Report) and Rani Therapeutics (NASDAQ:RANI – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.
Institutional and Insider Ownership
66.6% of Surrozen shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Surrozen and Rani Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Surrozen | $3.48 million | 56.54 | -$242.03 million | ($40.55) | -0.42 |
| Rani Therapeutics | $1.63 million | 67.22 | -$29.67 million | ($0.27) | -2.91 |
Rani Therapeutics has lower revenue, but higher earnings than Surrozen. Rani Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Surrozen and Rani Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Surrozen | 1 | 1 | 4 | 1 | 2.71 |
| Rani Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
Surrozen presently has a consensus price target of $45.00, suggesting a potential upside of 165.55%. Rani Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 1,013.23%. Given Rani Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Surrozen.
Risk and Volatility
Surrozen has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.
Profitability
This table compares Surrozen and Rani Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Surrozen | -2,885.33% | N/A | -93.62% |
| Rani Therapeutics | N/A | -104.60% | -65.17% |
Summary
Rani Therapeutics beats Surrozen on 8 of the 13 factors compared between the two stocks.
About Surrozen
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
